In the field of short peptides exploring anti-aging and organ-targeted regulation, Livagen and Pancragen are two highly regarded peptide biomodulators. Although both belong to the polypeptide class, they differ fundamentally in their amino acid sequences, target organs, and physiological functions.
**Differences in Amino Acid Sequence and Molecular Structure** The function of a polypeptide largely depends on its amino acid sequence. Livagen's amino acid sequence is Lys-Glu-Asp-Ala (KEDA), with the molecular formula C18H31N5O9 and a molecular weight of 461.5 g/mol. Pancragen's amino acid sequence is Lys-Glu-Asp-Trp (KEDW), with the molecular formula C26H36N6O9 and a molecular weight of 576.61. While the first three amino acids are the same, the difference in the fourth amino acid (alanine vs. tryptophan) determines their completely different biological characteristics and target organs.
**Differences in Target Organs and Main Functions** Livagen's core targets are concentrated in the immune system, gastrointestinal tract, and liver. It promotes protein synthesis and enhances cell activity by inducing chromatin decondensation (unpacking), activating age-silenced genes (such as ribosomal genes) in aging lymphocytes. Simultaneously, it regulates gene expression in the gastrointestinal tract and liver, achieving a holistic anti-aging effect from the inside out.
In contrast, Pancragen is a targeted regulator specifically for pancreatic cells. The pancreas is responsible for secreting digestive enzymes and hormones that regulate blood sugar (such as insulin). Pancragen specifically acts on pancreatic tissue, restoring the function of insulin receptors within cells and improving age-related glucose metabolism abnormalities. Furthermore, it stimulates the pancreas's self-protective mechanisms, enhancing its resistance to toxic substances such as alcohol and drugs, thereby preventing metabolic diseases such as pancreatitis.
Common Physicochemical Properties and Storage Requirements
Despite their different functions, both share a high degree of consistency in their physical form and storage requirements. They are typically white powders and, as polypeptides, have strict requirements for their storage environment. Both Livagen and Pancragen require storage at low temperatures (e.g., -20°C), under vacuum, protected from light, and in a dry environment to prevent peptide degradation and inactivation.
Application Scenarios and Compliance Restrictions Currently, the market circulation of both Livagen and Pancragen is strictly limited. They are primarily defined as "pharmaceutical intermediates" or for "laboratory scientific research" use only. This means they are not yet widely approved for clinical use as routine prescription drugs or dietary supplements for the general public. Procurement and use typically require appropriate research qualifications and strict adherence to relevant import/export and compliance policies.